Trial compares different doses of Merck's Zocor

11/9/2008 | Reuters

Scientists at the University of Oxford in the U.K. found that 80-mg doses of simvastatin, sold by Merck & Co. as Zocor, lowered "bad" LDL cholesterol by about 14% more than 20-mg doses during an average 6.7 years of treatment. Although researchers concluded that high-dose Zocor was safe, it was linked to 53 cases of myopathy, a muscle-weakening illness, compared with three patients who took lower doses.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR